Business
Preliminary Results
Preliminary Results.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 6360H Futura Medical PLC 14 March 2018 \n\n\n\n\n\nFor immediate release\n\n\n14 March 2018\n\n\n\n\n \n \nFutura Medical plc\n(\"Futura\" or \"the Company\")\n \nPreliminary Results for the year ended 31 December 2017\n \nFutura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce its preliminary results for the year ended 31 December 2017.\n \n \nDevelopment and Commercial Highlights:\nMED2002: Eroxon® - Treatment for erectile dysfunction (\"ED\")\n \n· Key meetings held and positive feedback received from US & European regulators on the two phase III trials planned in our clinical development programme\n \n· Interim pharmacokinetic data indicates that at least two higher strength doses of MED2002 are eligible for the planned Phase III clinical studies compared with the dose used in the successful Phase II study\n \n· Commercial out-licensing discussions at an advanced stage\n \nCSD500: Erectogenic condom\n \n· Successful product launch in Saudi Arabia with further order placed and in production\n \n· Further launches in 2018 underway\n \n \nTPR100 (diclofenac) and TIB200 (ibuprofen): Pain relief products\n \n· First out-licensing agreement signed for TPR100\n \n· Commercial out-licensing discussions continuing for other countries\n \n \nOrganisational and Financial Highlights:\n \n· Appointment of Angela Hildreth as Finance Director and Chief Operating Officer\n \n· Net loss of £3.90 million (2016: Net loss of £3.70 million), reflecting planned increase in R&D expenditure on the MED2002 clinical programme\n \n· Cash resources of £8.36 million at 31 December 2017 (31 December 2016: £12.35 million)\n \nJames Barder, Futu...